| scholarly article | Q13442814 |
| P2093 | author name string | David N Irani | |
| P2860 | cites work | B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5 | Q24309316 |
| Biomarkers of therapeutic response in multiple sclerosis: current status | Q27012726 | ||
| A chemokine-driven positive feedback loop organizes lymphoid follicles | Q28142202 | ||
| CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity | Q28217241 | ||
| UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes | Q28270473 | ||
| The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9 | Q28292044 | ||
| A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen | Q28300225 | ||
| Pathway analysis of primary central nervous system lymphoma | Q30481424 | ||
| The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. | Q33611768 | ||
| Development and maturation of secondary lymphoid tissues. | Q33652498 | ||
| The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). | Q33654152 | ||
| CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation | Q33803333 | ||
| Lymphoid chemokines in the CNS. | Q34020894 | ||
| Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. | Q34052870 | ||
| Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13. | Q34083294 | ||
| Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice | Q34110300 | ||
| Borrelia burgdorferi in the nervous system: the new "great imitator". | Q34169242 | ||
| Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma | Q48099867 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma | Q48462130 | ||
| Increased Meningeal T and Plasma Cell Infiltration is Associated with Early Subpial Cortical Demyelination in Common Marmosets with Experimental Autoimmune Encephalomyelitis. | Q48650442 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. | Q52022097 | ||
| Lack of NG2 exacerbates neurological outcome and modulates glial responses after traumatic brain injury. | Q52145462 | ||
| Enhanced expression of CXCL13 in human Helicobacter pylori-associated gastritis. | Q54367035 | ||
| Turning off follicular dendritic cells | Q59068710 | ||
| Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid | Q59543689 | ||
| Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin β receptor-Ig fusion protein | Q60455093 | ||
| Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial | Q61642982 | ||
| Cytologic features of cerebrospinal fluid in Lyme disease | Q69102060 | ||
| The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis | Q70045971 | ||
| Intrathecal immune response in patients with neuroborreliosis: specificity of antibodies for neuronal proteins | Q71978567 | ||
| Inoculation of nonhuman primates with the N40 strain of Borrelia burgdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease | Q72415603 | ||
| The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis | Q73536622 | ||
| Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of lyme disease | Q74045096 | ||
| Recent advances in chemokines and chemokine receptors | Q78165392 | ||
| B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones | Q81485944 | ||
| Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis | Q82505241 | ||
| A prospective study on the role of CXCL13 in Lyme neuroborreliosis | Q83663886 | ||
| CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis | Q83918246 | ||
| The chemokine CXCL13 in acute neuroborreliosis | Q84990890 | ||
| Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. | Q34191599 | ||
| The rhesus model of Lyme neuroborreliosis | Q34487753 | ||
| Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen | Q34488105 | ||
| CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses | Q34726022 | ||
| CXCL13 antibody for the treatment of autoimmune disorders | Q35086918 | ||
| The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system | Q35104199 | ||
| Chemokines in the systemic organization of immunity | Q35216944 | ||
| The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity | Q35216957 | ||
| Complexity of the microglial activation pathways that drive innate host responses during lethal alphavirus encephalitis in mice | Q35929137 | ||
| Pathogen specificity and autoimmunity are distinct features of antigen-driven immune responses in neuroborreliosis. | Q35949765 | ||
| CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation | Q36161486 | ||
| Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation | Q36174679 | ||
| CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. | Q36515088 | ||
| BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma | Q36762885 | ||
| Review of evidence for immune evasion and persistent infection in Lyme disease | Q36797128 | ||
| CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma | Q36907849 | ||
| Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis | Q36943086 | ||
| Demonstration of a B-lymphocyte mitogen produced by the Lyme disease pathogen, Borrelia burgdorferi | Q36957673 | ||
| Lymphoid chemokines in chronic neuroinflammation | Q37186200 | ||
| Possible role of glial cells in the onset and progression of Lyme neuroborreliosis | Q37356125 | ||
| Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease | Q38091729 | ||
| B cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factor. | Q38222302 | ||
| The primate autoimmune encephalomyelitis model; a bridge between mouse and man. | Q38497590 | ||
| Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke. | Q39258820 | ||
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. | Q39808939 | ||
| Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. | Q40390585 | ||
| The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis | Q40414775 | ||
| Novel lymphocyte-specific CC chemokines and their receptors. | Q41640121 | ||
| BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. | Q41740089 | ||
| The chemokine receptor CXCR5 is pivotal for ectopic mucosa-associated lymphoid tissue neogenesis in chronic Helicobacter pylori-induced inflammation | Q42202704 | ||
| Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides | Q42289168 | ||
| Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. | Q42772808 | ||
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. | Q43227358 | ||
| CXCL13 and CXCL12 in central nervous system lymphoma patients. | Q43272851 | ||
| Perivascular microenvironment in primary central nervous system lymphomas: the role of chemokines and the endothelin B receptor | Q44211720 | ||
| Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. | Q44999948 | ||
| Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. | Q46655434 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection | Q47603503 | ||
| Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome | Q47661648 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2016-10-05 | |
| P1433 | published in | Journal of Clinical & Cellular Immunology | Q27723807 |
| P1476 | title | Regulated Production of CXCL13 within the Central Nervous System | |
| P478 | volume | 7 |
| Q89909403 | Changes in expression of serum chemokine CXCL13 and IL-6 after hip replacement, and the relationship with lower limb vein thrombus |
| Q89847251 | Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction |
| Q57825775 | Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis |
| Q58798273 | The chemokine CXCL13 in cerebrospinal fluid in children with Lyme neuroborreliosis |
| Q92251928 | Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers |
Search more.